Oppenheimer & CO Inc Neu Base Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	BUY	$2.6 - $4.18 $14,040 - $22,572	5,400 Added 52.17%	15,750 $44,000
Q3 2021 Nov 12, 2021	SELL	$3.27 - $4.76 $7,848 - $11,424	-2,400 Reduced 18.82%	10,350 $37,000
Q2 2021 Aug 03, 2021	BUY	$4.63 - $7.34 $9,260 - $14,680	2,000 Added 18.6%	12,750 $61,000
Q1 2021 May 10, 2021	BUY	$6.92 - $12.36 $74,390 - $132,870	10,750 New	10,750 $79,000
Q4 2020 Feb 11, 2021	SELL	$6.92 - $9.25 $95,496 - $127,650	-13,800 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$7.25 - $9.71 $100,050 - $133,998	13,800 New	13,800 $105,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.